Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive, cutaneous neuroendocrine neoplasm with annual incidence rates of 0.13–1.6 cases/100,000/year worldwide as of 2018. Chemotherapy for metastatic MCC (mMCC) has high objective response rates (ORRs), but responses are not durable and overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatia, Shailender, Nghiem, Paul, Veeranki, S Phani, Vanegas, Alejandro, Lachance, Kristina, Tachiki, Lisa, Chiu, Kevin, Boller, Emily, Bharmal, Murtuza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394192/
https://www.ncbi.nlm.nih.gov/pubmed/35981787
http://dx.doi.org/10.1136/jitc-2022-004904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394192/
https://www.ncbi.nlm.nih.gov/pubmed/35981787
http://dx.doi.org/10.1136/jitc-2022-004904

Ejemplares similares